8-K: Tempest Therapeutics Receives Nasdaq Delisting Notice

Tempest Therapeutics received a Nasdaq delisting notice for failing to hold its annual meeting, but has scheduled the meeting for January 27, 2026, to regain compliance.

Summary

• Tempest Therapeutics, Inc. received a letter from The Nasdaq Stock Market LLC on January 8, 2026, indicating non-compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G).
• The non-compliance stems from the company's failure to hold an annual meeting of stockholders within twelve months of its fiscal year-end of December 31, 2024.
• The company has 45 calendar days from January 8, 2026, until February 23, 2026, to regain compliance or submit a plan to regain compliance.
• If a plan is accepted, Nasdaq may grant an exception of up to 180 calendar days from the fiscal year-end, or until June 29, 2026, to regain compliance.
• The 2025 Annual Meeting of Stockholders has been scheduled for January 27, 2026, and holding this meeting is expected to resolve the non-compliance.

Sentiment

Score: 5

Explanation: Neutral to slightly negative. While the issue is procedural and has a clear resolution path, receiving a delisting notice for a basic governance requirement is not ideal. The prompt scheduling of the annual meeting mitigates significant negative impact, suggesting no fundamental change to the company's operational or financial prospects.

Positives

• The company has already scheduled its 2025 Annual Meeting for January 27, 2026, demonstrating a clear and prompt plan to regain compliance with Nasdaq listing rules.
• Regaining compliance is a straightforward procedural matter that is expected to be resolved by holding the scheduled meeting.

Negatives

• The company received a formal notice of non-compliance from Nasdaq, indicating a lapse in corporate governance by failing to hold its annual meeting within the required timeframe.
• Failure to resolve the issue could lead to the delisting of the company's securities from The Nasdaq Stock Market LLC.

Risks

• Potential delisting from Nasdaq if the company fails to hold its annual meeting as scheduled or otherwise fails to regain compliance within the stipulated deadlines.
• Reputational damage due to a formal notice of non-compliance with basic corporate governance requirements.

Future Outlook

The company anticipates regaining full compliance with Nasdaq's continued listing requirements upon the successful holding of its 2025 Annual Meeting of Stockholders on January 27, 2026.

Management Comments

• Management has taken action to schedule the 2025 Annual Meeting of Stockholders for January 27, 2026, to address the Nasdaq non-compliance.

Industry Context

Receiving a delisting notice for failing to hold an annual meeting is a procedural issue that occasionally affects publicly traded companies, particularly smaller ones. While it signals a lapse in corporate governance, it is typically resolved quickly by scheduling and holding the overdue meeting. This event does not inherently reflect on the company's operational performance or financial health, but rather on its administrative compliance.

Comparison to Industry Standards

• Timely annual meetings are a fundamental aspect of corporate governance and a standard requirement for listed companies across global exchanges. Failure to meet this requirement, as seen with Tempest Therapeutics, deviates from industry best practices.
• Compared to peers, a company receiving such a notice indicates a temporary administrative oversight, which, if promptly corrected, typically has minimal long-term impact on investor perception or operational standing.

Corporate Governance

Stakeholder Impact

• Shareholders: May experience temporary concern regarding the company's listing status, but this should be alleviated by the scheduled annual meeting.
• Regulatory Authorities: Nasdaq has issued a formal notice, requiring the company to demonstrate compliance.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on January 27, 2026.
• Regain compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G).

Key Dates

Recommendation

The delisting notice is a procedural issue related to corporate governance, specifically the delayed annual meeting. However, the company has already scheduled the meeting for January 27, 2026, which is expected to resolve the non-compliance. This indicates a prompt and effective response to a minor governance lapse, suggesting no fundamental change to the company's operational or financial prospects. Investors should monitor the successful execution of the annual meeting, but the immediate impact on valuation is likely minimal.

Keywords

Tempest Therapeutics, Nasdaq, Delisting, Annual Meeting, Corporate Governance, SEC Filing, 8-K, TPST